Fovea Enters into Research Agreement with Genzyme
Fovea Pharmaceuticals SA (Paris, France) has entered into a collaborative research agreement with Genzyme Corporation (Cambridge, MA). The alliance is anchored around Fovea's proprietary high content technology platform that allows the identification of new targets involved in photoreceptor degeneration in retinal dystrophies.
Fovea Pharmaceuticals SA (Paris, France) has entered into a collaborative research agreement with Genzyme Corporation (Cambridge, MA). The alliance is anchored around Fovea’s proprietary high content technology platform that allows the identification of new targets involved in photoreceptor degeneration in retinal dystrophies. The companies will collaborate to develop gene related therapies using Fovea selected targets and Genzyme gene delivery technologies.
The ultimate cause of irreversible blindness in major retinal diseases is photoreceptor degeneration. According to the Foundation Fighting Blindness, rare inherited retinal dystrophies like Stargardt’s disease or Retinitis pigmentosa are recognized as the most common inherited causes of blindness in people below the age of 50, affecting approximately 1.5 million people worldwide. In addition, in more common retinal disorders like the dry form of age related macular degeneration, sight loss ultimately results from photoreceptor degeneration.
In this complementary partnership, Fovea’s scientific, clinical, and pharmaceutical expertise in retinal diseases and Genzyme’s extensive know-how in protein production and gene delivery will offer customized solutions for the understanding of the disease mechanisms, with the goal to develop new therapeutic strategies to prevent or reduce the severity of blindness.
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
